NCT02623621View on ClinicalTrials.gov

Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer

CompletedOBSERVATIONAL

Enrollment

103

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

December 31, 2017

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

chemotherapy plus bevacizumab

Every chemotherapy regimen combined with bevacizumab is allowed

Trial Locations (1)

56126

Azienda Ospedaliero Universitaria Pisana, Pisa

All Listed Sponsors

lead

Azienda Ospedaliero, Universitaria Pisana

OTHER

NCT02623621 - Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter